Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports

Abstract Background Nivolumab is an immune checkpoint inhibitor specific to the programmed death 1 (PD-1) receptor. Nivolumab has shown clinical responses in many malignancies. Although immune-related adverse events (irAEs) associated with nivolumab are largely tolerable, severe irAEs have occurred...

Full description

Bibliographic Details
Main Authors: Koji Yoshino, Takayuki Nakayama, Ayumu Ito, Eiichi Sato, Shigehisa Kitano
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Cancer
Subjects:
Autoimmune colitis
Nivolumab
Immune-related adverse event
Biomarker
C-reactive protein
Case report
Online Access:http://link.springer.com/article/10.1186/s12885-019-6138-7

Internet

http://link.springer.com/article/10.1186/s12885-019-6138-7

Similar Items